NCT03820180 is a Phase 1 clinical trial of Test Product in Bioequivalence, sponsored by Respirent Pharmaceuticals Co Ltd..

Who is sponsoring NCT03820180?

NCT03820180 is sponsored by Respirent Pharmaceuticals Co Ltd..

What drugs are being tested in NCT03820180?

Interventions in NCT03820180: Test Product, Reference Product.

What condition does NCT03820180 study?

NCT03820180 studies Bioequivalence.

Is NCT03820180 still recruiting?

NCT03820180 is currently completed. Last updated 27 March 2019.

Last reviewed 2019-03-27 · How we verify

NCT03820180

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Bioequivalence Study Between Fluticasone Propionate 250 mcg and Salmeterol Xinafoate 50 mcg Inhalation Powder/Respirent Pharmaceuticals vs. ADVAIR DISKUS® 250/50 Inhalation Powder/GSK in Healthy Volunteers

Completed Phase 1 Last updated 27 March 2019

What this trial tests

Phase 1 trial testing Test Product in Bioequivalence in 34 participants. Completed in 19 February 2019.

Timeline

23 January 2019

Primary endpoint
12 February 2019

19 February 2019

Quick facts

Lead sponsor	Respirent Pharmaceuticals Co Ltd.
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	crossover
Masking	single
Primary purpose	other
Enrollment	34
Start date	23 January 2019
Primary completion	12 February 2019
Estimated completion	19 February 2019
Sites	1 location across Greece

Drugs / interventions tested

Test Product — full drug profile →
Reference Product — full drug profile →

Conditions studied

Bioequivalence — all drugs for Bioequivalence →

Sponsor

Respirent Pharmaceuticals Co Ltd. — full company profile →

Who can join

Adults 18 to 60, any sex, with Bioequivalence. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Bioequivalence study between two inhaler products of fixed dose combination of fluticasone propionate and salmeterol xinafoate inhalation powder

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Test Product

Trials testing the same drug.

NCT05370196 — Synthetic Male Condom Slippage-Breakage Study · NA · completed
NCT05372900 — Nutritional Intervention to Improve Sleep Quality and Improve Next-day Mood and Cognitive Benefits · NA · completed
NCT04466176 — A Pivotal Bioequivalence Study Between Fluticasone Propionate 250 mcg and Salmeterol Xinafoate 50 mcg Inhalation Powder/ · Phase 1 · completed
NCT03975166 — A Bioequivalence Study Between Fluticasone Propionate 100 mcg and Salmeterol Xinafoate 50 mcg Inhalation Powder/Respiren · Phase 1 · completed
NCT04051710 — Clinical Pharmacodynamic Bioequivalence Study of Beclomethasone Dipropionate 40 mcg INH · Phase 3 · completed

Other recruiting trials for Bioequivalence

Currently open trials in the same condition.

NCT07096869 — Bioequivalence Study of Paclitaxel Protein-bound Particles for Injectable Suspension (Albumin-bound) in Breast Cancer Pa · Phase 1 · recruiting

Other Respirent Pharmaceuticals Co Ltd. trials

Trials by the same sponsor.

NCT06025214 — Bioequivalence Study for Fluticasone Propionate 500 mcg/Salmeterol Xinafoate 50 mcg Inhalation Powder in Healthy Volunte · Phase 1 · unknown
NCT05982990 — Bioequivalence Study for Fluticasone Propionate 250 mcg/Salmeterol Xinafoate 50 mcg Inhalation Powder in Healthy Volunte · Phase 1 · unknown
NCT05697003 — Bioequivalence Study for Fluticasone Propionate 100 mcg/Salmeterol Xinafoate 50 mcg Inhalation Powder in Healthy Volunte · Phase 1 · unknown
NCT05664061 — Bioequivalence With Clinical Endpoint Study of Fluticasone Propionate 100 mcg and Salmeterol 50 mcg Inhalation Powder/Re · Phase 3 · unknown
NCT05397834 — A Bioequivalence Study Between Fluticasone Propionate 250 mcg/Blister Oral Inhalation Powder/Respirent Pharmaceuticals v · Phase 1 · unknown

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03820180 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Respirent Pharmaceuticals Co Ltd.
Last refreshed: 27 March 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03820180.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing